Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IVD SECTOR QUARTERLIES ROUND-UP: Spending spree puts Inverness in red for Q4

This article was originally published in Clinica

Executive Summary

Charges resulting from a busy year of acquisition and integration activities have led to Inverness Medical Systems posting a net loss for the fourth quarter of 2007. The Waltham, Massachusetts-based diagnostics specialist recorded a deficit of $12.5m, a significant drop compared to the profit of $6m it made over the same period in 2006. Inverness' fourth-quarter net revenue rose by 83% to approximately $288m, largely helped by contributions from acquired businesses which boosted sales of the company's professional diagnostics products. This core business segment generated $234.2m in revenue ($139.3m derived from acquired product lines), a sharp rise compared to the same period in 2006, during which it made $87.2m.

You may also be interested in...

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts